Travere’s Sparsentan Faces Slower Uptake Due To Liver Monitoring Requirement
Firm Thinks Unmet Need Will Ensure Commercial Success
The FDA required an updated REMS for liver monitoring out of caution over potential liver toxicity, though the drug has not caused drug-induced liver injury in development to date.
You may also be interested in...
Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.
Travere Therapeutics is aiming to provide a new foundational therapy for IgAN patients with its novel non-immunosuppressive agent, Filspari, as it prices it at a discount to Calliditas’s rival Tarpeyo, ahead of looming further competition.
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.